Advertisement

Topics

US nod for CSL Behring’s HAE prevention therapy

05:58 EDT 23 Jun 2017 | PharmaTimes

US regulators have approved CSL Behring’s Haegarda, the first C1 esterase inhibitor for subcutaneous administration to prevent hereditary angioedema (HAE) attacks in adolescent and adults

Original Article: US nod for CSL Behring’s HAE prevention therapy

NEXT ARTICLE

More From BioPortfolio on "US nod for CSL Behring’s HAE prevention therapy"

Advertisement
Quick Search
Advertisement
Advertisement